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advice for women who are overweight or obese
on maternal diet and physical activity: the LIMIT
randomised trial
Jodie M Dodd1,2*, Courtney Cramp1, Zhixian Sui1, Lisa N Yelland1,3,4, Andrea R Deussen1, Rosalie M Grivell1,2,
Lisa J Moran1, Caroline A Crowther1,8, Deborah Turnbull5, Andrew J McPhee6, Gary Wittert7, Julie A Owens1,
Jeffrey S Robinson1 and For the LIMIT Randomised Trial GroupAbstract
Background: Overweight and obesity is a significant health concern during pregnancy. Our aim was to investigate
the effect of providing antenatal dietary and lifestyle advice to women who are overweight or obese on
components of maternal diet and physical activity.
Methods: We conducted a randomised controlled trial, in which pregnant women with a body mass index ≥25 kg/m2,
and singleton gestation between 10+0 to 20+0 weeks were recruited and randomised to Lifestyle Advice
(involving a comprehensive dietary and lifestyle intervention over their pregnancy) or Standard Care. Within the
intervention group, we conducted a nested randomised trial in which a subgroup of women were further
randomised to receive access to supervised group walking sessions in addition to the standard information
presented during the intervention contacts (the Walking group) or standard information only.
The outcome measures were maternal dietary intake, (including food groups, macronutrient and micronutrient
intake, diet quality (using the Healthy Eating Index; HEI), dietary glycaemic load, and glycaemic index) and
maternal physical activity. Women completed the Harvard Semi-Structured Food Frequency Questionnaire, and
the Short Questionnaire to Assess Health-enhancing Physical Activity (SQUASH), at trial entry, 28 and 36 weeks’
gestational age, and 4 months postpartum.
Analyses were performed on an intention-to-treat basis, using linear mixed effects models with adjustment for
the stratification variables.
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Results: Women randomised to Lifestyle Advice demonstrated a statistically significant increase in the number
of servings of fruit and vegetables consumed per day, as well as increased consumption of fibre, and reduced
percentage energy intake from saturated fats (P < 0.05 for all). Maternal HEI was significantly improved at both
28 (73.35 ± 6.62 versus 71.86 ± 7.01; adjusted difference in means 1.58; 95% CI 0.89 to 2.27; P < 0.0001) and 36
(72.95 ± 6.82 versus 71.17 ± 7.69; adjusted difference in means 1.77; 95% CI 1.01 to 2.53; P < 0.0001) weeks. There
were no differences in dietary glycaemic index or glycaemic load. Women randomised to Lifestyle Advice also
demonstrated greater total physical activity (adjusted difference in means 359.76 metabolic equivalent task units
(MET) minutes/week; 95% CI 74.87 to 644.65; P = 0.01) compared with women receiving Standard Care. The
supervised walking group was poorly utilised.
Conclusions: For women who are overweight or obese, antenatal lifestyle advice improves maternal diet and
physical activity during pregnancy.
Please see related articles: http://www.biomedcentral.com/1741-7015/12/163 and http://www.biomedcentral.
com/1741-7015/12/201.
Trial registration: Australian and New Zealand Clinical Trials Registry (ACTRN12607000161426)
Keywords: Pregnancy, Overweight and obesity, Diet composition, Physical activity, Randomised trial, Dietary
and lifestyle interventionBackground
Obesity is recognised as a significant global health problem
[1], with well-documented risks for pregnant women and
their infants, which rise with increasing maternal body
mass index (BMI) [2,3]. Current clinical care guidelines
indicate that ideally, women should be counselled prior to
conception about the increased pregnancy risks associated
with obesity, and encouraged to make lifestyle changes to
reduce the risk of subsequent complications during preg-
nancy and childbirth through weight loss [4,5]. However,
with data from Australia, the USA and UK suggesting more
than 50% of women enter pregnancy with a BMI in excess
of 25 kg/m2 [4,6,7], considerable attention has been di-
rected towards evaluating interventions to limit gestational
weight gain, and their effect on maternal and infant health
outcomes [8-10]. Research has focused on the effects of
dietary and lifestyle interventions to limit gestational weight
gain, particularly among women who are overweight or
obese [8-10], and there is limited information to date
relating specifically to the effective components of these
antenatal interventions, with suggestions that interventions
designed to limit gestational weight gain through modifica-
tion of diet may be more effective than those designed to
increase physical activity alone [10].
Dietary quality can be assessed by utilising a number
of different tools, including principal component analysis
and use of dietary quality indices comparing nutritional
intake with recommendations for healthy eating or dietary
guidelines. A decrease in dietary quality, when utilising
these measures as a comprehensive indicator of dietary in-
take, is associated with increased weight gain over time
[11], as well as increased all-cause mortality and morbidityrisk, specifically in relation to cardiovascular disease and
some malignancies [12]. Compared with women of normal
BMI, women who are overweight or obese demonstrate
poorer diet quality during pregnancy [13], which continues
into the early postpartum period [14]. When specifically
compared with women of healthy weight, pregnant women
who are overweight or obese demonstrate reduced intake
of grains, vegetables, iron and folate [13,15,16]. With regard
to clinical outcomes, poor diet quality during pregnancy
has been associated with an increased risk of adverse
pregnancy outcomes, including glucose intolerance and
pre-eclampsia [17].
Dietary glycaemic index (GI) was developed as a tool for
individuals with diabetes [18], ranking the post-prandial
glycaemic response to ingested carbohydrates against a
reference of either pure glucose or white bread, and the gly-
caemic load (GL) is the product of the glycaemic index and
the amount of dietary carbohydrate [19]. Consumption of
foods with low glycaemic index have been shown to be as-
sociated with reduced carbohydrate-induced post-prandial
glycaemia [20]. Furthermore, a low glycaemic index or gly-
caemic load diet has been associated with improved weight
loss through potential effects on hunger and energy intake
[21]. Of relevance to pregnant women is the effect of ma-
ternal glycaemia on the placental transfer of glucose to the
fetus, acting as a substrate for growth and development.
While some studies have identified associations between
maternal consumption of a low glycaemic index or gly-
caemic load diet and lower gestational weight gain [22,23]
or lower infant birth weight [24], these findings are not uni-
versal, with other studies demonstrating no effect on infant
birth weight [23,25-27].
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improving maternal wellbeing and cardiovascular perform-
ance [28,29]. More specifically, exercise in pregnancy has
been associated with a reduction in the risk of gestational
diabetes [30,31], pre-eclampsia [32], and operative birth
[33], and with improvements in fetal growth [34,35]. The
American College of Obstetricians and Gynecologists
(ACOG) has advocated that all pregnant women, without
contraindications to exercising, should be active and par-
ticipate in mild-to-moderate exercise for at least 30 minutes
on most days of the week [36]. However, the recommenda-
tions for women who have been previously inactive or who
have pregnancy complications are less clear-cut, requiring
individual consideration [36]. ACOG recommend that
pregnant women who are overweight or obese should
be encouraged to follow an exercise programme in
order to optimise health outcomes for both the woman
and her infant [37]. Despite the proposed benefits of
exercise, physical activity has been reported to decline
over the course of pregnancy among women of all BMI
categories, but is particularly evident among women
who are overweight or obese [38-40], with a large pro-
portion of women not attaining the recommended
amount of exercise.
The primary findings of the LIMIT randomised trial
evaluating the provision of antenatal dietary and lifestyle
advice to women who were overweight or obese, have
been reported previously, and indicate a significant 18%
relative risk reduction in the chance of an infant being
born with birth weight above 4 kg [41]. We now report
the effect of providing antenatal dietary and lifestyle advice
on specific components of maternal diet, including food
groups, macronutrient and micronutrient consumption,
dietary quality, and dietary glycaemic load and index, and
maternal physical activity.
Methods
Ethics
Ethics approval was granted by the Women’s and Children’s
Local Health Network Human Research and Ethics
Committee at the Women’s and Children’s Hospital,
the Central Northern Adelaide Health Service Ethics
of Human Research Committee (Lyell McEwin Hospital)
and the Flinders Clinical Research Ethics Committee
(Flinders Medical Centre). All participants provided
written informed consent.
Study design
The study was a multicentre randomised trial across
the three major metropolitan maternity hospitals within
Adelaide, South Australia. The methods [42] and primary
findings [41] of the LIMIT randomised trial have been
reported previously, and the trial has been registered on
the Australian and New Zealand Clinical Trials Registry(ACTRN12607000161426). Additional dietary and phys-
ical activity outcomes were added to the final working
protocol, reflecting piloting and feasibility assessment, and
finalization of specific questionnaires. These amendments
were pre-specified in the final working protocol, early in
the conduct of the trial, and prior to any analyses being
undertaken.
Inclusion and exclusion criteria
Women with a BMI ≥25 kg/m2 and singleton pregnancy
between 10+0 and 20+0 weeks gestation were eligible for
enrolment. Women with a multiple pregnancy, or with type
1 or 2 diabetes diagnosed prior to pregnancy, or who were
unable to provide informed consent were ineligible.
Trial entry
All women presenting for antenatal care had their height
and weight measured and their BMI calculated at the first
antenatal appointment. Eligible women were presented
with written information, and were encouraged to discuss
participation with their primary support person.
Randomisation, masking and group allocation
Randomisation occurred by telephoning the central ran-
domisation service, which utilised a computer-generated
schedule, with balanced variable blocks. Stratification oc-
curred for parity (0 versus ≥1), BMI at antenatal booking
(25 to 29.9 kg/m2 versus ≥30 kg/m2), and collaborating
centre. Women were randomised and allocated to either
‘Lifestyle Advice’ or ‘Standard Care’.
Nested randomised trial
Between January 2010 and September 2011, we conducted
a nested randomised trial, in which women who were ran-
domised to the Lifestyle Advice group underwent further
randomisation to receive either written and verbal infor-
mation about physical activity (Lifestyle Advice Group),
or to additionally be invited to participate in a targeted,
supervised walking group (Walking group).
Treatment schedules
Lifestyle Advice group
Women randomised to receive Lifestyle Advice participated
in a comprehensive dietary and lifestyle intervention over
the course of their pregnancy, which included a combin-
ation of dietary, physical activity and behavioural strategies,
delivered by a research dietician and trained research assis-
tants [42]. Within 2 weeks of randomisation, the women
attended a planning session with a research dietician, dur-
ing which a detailed dietary and physical activity history
was obtained.
Women were provided with dietary advice consistent with
current Australian standards [43]: to maintain a balance of
carbohydrates, fat and protein; to reduce intake of foods high
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intake of fibre; and to promote consumption of two servings
of fruit, five servings of vegetables, and three servings of dairy
each day [43]. Information was individualised, and included
meal plans, healthy recipes that were quick to prepare, simple
food substitutions (including reducing intake of sugar-
sweetened soft drinks and fruit juices, reducing added sugar
and foods high in refined carbohydrates, and using low-fat al-
ternatives), healthy snack and eating-out options, and guide-
lines for healthy food preparation.
Physical activity advice focused on the benefits of exercise in
pregnancy, potential safety concerns relating to exercise during
pregnancy, tips to increase incidental activity and walking, and
promoting recreational, aerobic and strength-conditioning ex-
ercises that are appropriate during pregnancy [44].
Women were encouraged to set achievable goals for
dietary and physical activity change, supported to make
these lifestyle changes, and asked to self-monitor their pro-
gress through the use of a workbook. Women were encour-
aged to identify potential barriers to implementation of
their dietary goals. Using these perceived barriers, women
were assisted to problem-solve, and to develop individua-
lised strategies to facilitate their successful implementation.
This information was reinforced during subsequent inputs
provided by the research dietician (at 28 weeks’gestation) and
trained research assistants (via telephone call at 22, 24, and
32weeks’gestation and a face-face visit at 36 weeks’gestation).
Walking group (nested randomised controlled trial)
Women within the Lifestyle Advice group who had been fur-
ther randomised to theWalking groupwere invited to partici-
pate in a targeted, supervised walking group, in addition to
receiving the written and verbal information provided to all
women assigned to the Lifestyle Advice group, as described
above. TheWalking group was designed to enable women to
increase their level of physical activity through a simple form
of exercise that could in future be performedwithout supervi-
sion, and that did not present a health risk to the pregnant
woman or her unborn infant. Women were encouraged to
participate three times per week, and to attend with a support
person, under the guidance of a trained researcher.
There were three outdoor walking locations in the Adelaide
metropolitan area, and two indoor walking locations in shop-
ping centres. Indoor treadmill walking was provided at no cost
as an alternative when theweather was not suitable for outdoor
walking. Each walking session was designed to cover a distance
of approximately 4.2 km, and was of 40 minutes duration (in-
cluding 5 minutes of general stretching and warming up,
followed by 5 minutes of cooling down time at the end of each
session). The intensity ofwalkingwasmoderate, consistentwith
recommendations in pregnancy [45]. During the walking ses-
sion, womenwere provided with the opportunity to discuss the
importance and effects of physical activity duringpregnancy, in-
cluding the optimal amount and intensity of home exercise.Standard Care group
Women randomised to receive Standard Care continued
their pregnancy care according to local hospital guide-
lines, which did not include routine provision of advice
related to diet, exercise, or gestational weight gain.
Study endpoints: maternal diet
The pre-specified endpoints related to maternal dietary
intake were
 Food groups
 Macronutrient intake
 Micronutrient intake
 Healthy Eating Index (HEI)
 Dietary Glycaemic Load and Index
All women were asked to complete the Harvard
Semi-quantitative Food Frequency questionnaire (the
Willett questionnaire) at the time of study entry, at 28
and 36 weeks’ gestational age, and at 4 months post-
partum. The Willett questionnaire was developed in
1985 in the USA to measure the daily intake of nutri-
ents from 126 food items, with an indication of stand-
ard portion size, divided into seven food groups [46],
and has been validated for use during pregnancy [47],
and in an Australian pregnancy setting [48]. Questions
were asked about the relative frequency of consumption of
specific food items, use of supplements, cooking methods
used and addition of sugar to foods. An open-ended ques-
tion allowed record of consumption of other foods, which
were then categorised by the study investigators. Daily
nutrient intakes were estimated by multiplying frequency
responses by the nutrient compositions of the specified
portion size of each food item according to Australian
food composition tables [49], reflecting standard food for-
tification with both folate and iodine. To assess adherence
to dietary recommendations, food and drink consumption
was grouped into food groups as defined by the Australian
Guide to Healthy Eating [43]. Foods that did not fit into
the five core food groups were classed as ‘non-core
foods’ being higher in fat, sugar and salt, and providing
minimal nutrients [43].
For the questionnaire completed at study entry, women
were asked to indicate how often on average they had con-
sumed the amount of food during the past year. For the
questionnaires completed at 28 and 36 weeks and postpar-
tum, women were asked to indicate how often on average
they had consumed the amount of food since the previous
questionnaire was completed.
Micronutrient values were obtained from the Willett
questionnaire and analysed as mean intakes, utilising
the Food Works Nutrient Analysis Software Package
(FoodWorks, v.7 Professional; Xyris Software 2012;
Australia) incorporating Australian food composition tables.
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consisting of 12 components, with a maximum score of
100. Total fruit (including 100% juice), whole fruits, total
vegetables, dark-green and orange vegetables and legumes,
total grains and whole grains categories have a score out
of 5; milk, meat and beans, oils, saturated fat and sodium
have scores out of 10; and calories from solid fats, alcoholic
beverages and added sugars (SoFAAS) have a score out
of 20. A HEI score above 80 is considered good, a score
between 50 and 80 needs improvement, and scores
below 50 are considered poor. The HEI has been validated
for use in a pregnant population [51].
GI values were obtained from the Willett questionnaire
and analysed as mean intakes, utilising the Food Works
Nutrient Analysis Software Package (as above), incorpor-
ating Australian food composition tables and published
glycaemic index values. Dietary glycaemic index was deter-
mined as the sum of the glycaemic index for all carbohy-
drates consumed in the diet, with a proportional weighting
to account for the relative contribution of each food.
Study endpoints: maternal physical activity
Women completed the Short Questionnaire to Assess
Health-enhancing Physical Activity (SQUASH) [52] at trial
entry, 28 and 36 weeks’ gestation, and 4 months postpar-
tum. The questionnaire comprises 11 questions evalu-
ating time spent on different types of physical activity
(including commuting, leisure, household and incidental,
and work-related activities), has been validated against
accelerometer data [52], and has been used during
pregnancy [53] and the post-partum period [54]. An
activity-specific intensity code from the Compendium of
Physical Activities [55] was assigned to each reported ac-
tivity, and a corresponding estimate of intensity in meta-
bolic equivalent task units (METs) was determined, where
1 MET is equal to the energy expended during quiet sit-
ting [55]. The number of minutes spent in each reported
activity was multiplied by its MET intensity, and summed
to calculate total daily energy expenditure. Because MET
is a measure of intensity and rate of physical activity, the
concept of the MET-minute was used to quantify the total
amount of physical activity in a comparable way between
individuals and across activities [55]. As the SQUASH
questionnaire reports physical activity during an aver-
age week, MET-minutes per week (METs/week) were
calculated as duration (min) × frequency (days/week)
of MET intensity.
Analysis and reporting of results
Analyses were performed on an intention-to-treat basis.
Women were included in the analysis if they returned
one or more ‘valid’ questionnaires, and did not withdraw
consent to use their data or did not have a miscarriage,
termination of pregnancy, or stillbirth. Diet questionnaireswere considered invalid if over 25% of responses were
missing or if total energy intake was unrealistic (<4,500 kJ
or >20,000 kJ) [56]. Physical activity questionnaires were
considered invalid if the total hours of activity reported
per week exceeded the number of hours in a week.
Outcomes were analysed using linear mixed effects
models including treatment group, time, and their
interaction, with adjustment made for the stratification
variables centre, parity and BMI as fixed effects. Out-
comes measured on different subjects were assumed to
be independent, but outcomes measured on the same
subject across the four time points were allowed to be
correlated by specifying an unstructured covariance
matrix for the error term. Baseline differences were
allowed between treatment groups, as questionnaires
were completed after women had been notified of their
treatment group allocation, which may have influenced
their responses. When the treatment × time interaction
was significant, post hoc tests were performed to assess
the effect of treatment group at each time point. When the
interaction was not significant, it was removed from the
model, and the main effect of treatment group was esti-
mated. Exploratory analyses were also conducted to assess
whether the effect of treatment varied by BMI category
(overweight versus obese), by including an interaction
between treatment group, time and BMI category
(where the effect of treatment varied over time) or an
interaction between treatment group and BMI category.
Statistical significance was assessed at the two-sided
P < 0.05 level, and no adjustment was made for multiple
comparisons. All analyses were performed using SAS soft-
ware (v9.3; SAS Inc., Cary, NC, USA).
Sample size
The sample size of 2,180 women was pre-determined based
on the primary outcome of the trial (large for gestational
age infant) as reported previously [41].
Results
Between June 2008 and December 2011, we recruited and
randomised 2,212 women, with 1,108 allocated to receive
Lifestyle Advice and 1,104 Standard Care. There were 2,142
women (1,075 Lifestyle Advice; 1,067 Standard Care) avail-
able for inclusion in the analyses, after excluding women
who withdrew consent to use their data (10 women) or
had a miscarriage, termination of pregnancy or stillbirth
(60 women) [41]. At least one valid dietary questionnaire
[56] was received from 945 women (87.9%) in the Lifestyle
Advice group, and 928 women (87.0%) in the Standard
Care group. At least one valid physical activity question-
naire was received from 974 women (90.6%) in the Lifestyle
Advice group, and 950 women (89.0%) in the Standard
Care group who were included in the analyses (Figure 1).
Baseline characteristics of the women who completed
Figure 1 Flow of participants through the trial.
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(Table 1) and to the full randomised groups [41]. Number of
questionnaires returned at each time point (study entry, 28
and 36 weeks’ gestational age, and at 4 months postpartum)
are shown in Additional file 1: Table S1.
Macronutrient consumption and food groups
There was no statistically significant difference identified
in the average daily energy consumption between women
receiving Lifestyle Advice and women receiving Standard
Care (Table 2). However, women randomised to receive
Lifestyle Advice demonstrated a significant increase in the
number of servings per day of fruit overall and vegetables
after trial entry, compared with women receiving Standard
Care. Additionally, women receiving Lifestyle Advice
increased their consumption of dietary fibre, while sig-
nificantly reducing the percentage of their energy intake
derived from saturated fats overall compared with women
receiving Standard Care. There was no evidence to suggest
that the intervention effect was modified by maternal BMI
category (data not shown).
Micronutrient consumption
Women randomised to the Lifestyle Advice group dem-
onstrated improvements in their dietary micronutrientintake. During pregnancy, women in the Lifestyle Advice
group reported greater intake of calcium, potassium and
vitamin B2, but this was not maintained postpartum
(Table 3). These women also increased their consumption
of vitamin A, vitamin C and folate overall, compared with
women in the Standard Care group (Table 3). No significant
changes were observed for other micronutrients. There was
some evidence to suggest that the effect of the intervention
on iodine, vitamin E and folate intake was modified by
maternal BMI category (interaction P < 0.05 in all cases),
with overall intake significantly increased in obese but not
overweight women randomised to the Lifestyle Advice
group (data not shown).
Healthy Eating Index
Women randomised to receive Lifestyle Advice demon-
strated significant improvement in their diet quality as
measured by the HEI, at both 28 and 36 weeks’ gesta-
tion, compared with women receiving Standard Care
(Table 4). Specifically, women receiving Lifestyle Advice
significantly increased their consumption of total fruit,
whole fruit, and dark-green and orange vegetables and
legumes, compared with women receiving Standard
Care. With the exception of improved consumption of
dark-green and orange vegetables and legumes, these
Table 1 Demographic and clinical characteristics at trial entry
Characteristic Lifestyle advice (n = 974) Standard care (n = 950) Total (n = 1924)
Maternal age, yearsa 29.4 ± 5.4 29.6 ± 5.4 29.5 ± 5.4
Gestational age at entry, weeksb 14.3 (12.0 to 17.0) 14.3 (12.0 to 17.1) 14.3 (12.0 to 17.1)
Body mass index category, n (%)
25.0 to 29.9 410 (42.1) 421 (44.3) 831 (43.2)
30.0 to 34.9 282 (29.0) 268 (28.2) 550 (28.6)
35.0 to 39.9 180 (18.5) 155 (16.3) 335 (17.4)
≥40.0 102 (10.5) 106 (11.2) 208 (10.8)
Public patient, n (%) 954 (97.9) 927 (97.6) 1881 (97.8)
Caucasian, n (%) 883 (90.7) 866 (91.2) 1749 (90.9)
Smoker, n (%) 124 (12.7) 97 (10.2) 221 (11.5)
Nulliparous, n (%) 410 (42.1) 385 (40.5) 795 (41.3)
Index of Socio-economic Disadvantage, n(%)c
Unknown 2 (0.2) 1 (0.1) 3 (0.2)
Quintile 1 (most disadvantaged) 296 (30.4) 274 (28.8) 570 (29.6)
Quintile 2 231 (23.7) 236 (24.8) 467 (24.3)
Quintile 3 157 (16.1) 143 (15.1) 300 (15.6)
Quintile 4 138 (14.2) 151 (15.9) 289 (15.0)
Quintile 5 (least disadvantaged) 150 (15.4) 145 (15.3) 295 (15.3)
aMean ± standard deviation.
bMedian (interquartile range).
cIndex of Socio-economic - disadvantage as measured by SEIFA (socioeconomic indexes for areas [57]).
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tum. The intervention was not associated with changes
in consumption of grains, meat and beans, oils, sodium,
or caloric intake from SoFAAS. There was no evidence
of modification of the intervention effect by maternal
BMI category (data not shown).
Glycaemic index and glycaemic load
There were no statistically significant differences identified
in dietary glycaemic load or dietary glycaemic index be-
tween women receiving Lifestyle Advice and women receiv-
ing Standard Care (Table 5). There was also no evidence of
modification of the intervention effect by maternal BMI
category (data not shown).
Physical activity
Women randomised to receive Lifestyle Advice demon-
strated a significant overall improvement in total physical
activity, compared with women receiving Standard Care
(Table 6). This finding was driven by an overall increase in
household activity, with some evidence of an increase in
leisure activity also, and represented an additional 15 to
20 minutes brisk walking on most days of the week.
Commuting and work-related activities were similar be-
tween groups and at each time point for women who
engaged in these activities (data not shown). No changes
in treatment effects over time were identified for anytypes of activity (Table 6). There was some evidence to
suggest that the effect of the intervention was modi-
fied by maternal BMI category for total physical activity
(P = 0.043), with women who were obese demonstrating
the greatest increase in total physical activity (adjusted
difference in means 617.20 MET-minutes/week; 95% CI
238.48 to 995.92; P = 0.001).
Nested randomised trial
During the specified time period, 582 eligible women from
the Lifestyle Advice group were further randomised, 287 to
the Walking group, and 295 to the Lifestyle group. Baseline
characteristics of the women who participated in the nested
randomised trial are included in Additional file 2: Table S2
and were similar between treatment groups. There were
580 women (286 Walking group; 294 Lifestyle group)
available for inclusion in the analyses, after 1 woman
had a miscarriage, and 1 woman withdrew consent to util-
ise her data. At least 1 valid physical activity questionnaire
was received from 257 women in the Walking group
(89.9%), and 269 women (91.5%) in the Lifestyle group
(Figure 2). At trial entry, the characteristics of the women
included in the analysis were similar between treatment
groups (data not shown).
Of the women randomised to the Walking group,
190 (66%) subsequently declined to participate in the
Walking group when contacted despite their initial
Table 2 Food group and macronutrient consumption: between treatment group comparisona
Outcome Time point Lifestyle advice
(n = 945)b
Standard
care (n = 928)b
Adjusted
treatment × time
interaction P-valuec
Adjusted treatment effect
P 95% CI
Total energy, kJd Trial entry 8678.89 (2690.39) 8501.40 (2565.19) 0.99 0.09 178.60 (−26.56 to 383.77)
28 weeks 8772.33 (2545.60) 8675.26 (2792.00)
36 weeks 8667.72 (2585.28) 8568.86 (2751.49)
4 months 8763.08 (2694.71) 8628.89 (2686.06)
Breads and cereals,
servings/dayd
Trial entry 2.63 (1.45) 2.61 (1.43) 0.82 0.27 0.06 (−0.04 to 0.16)
28 weeks 2.65 (1.34) 2.59 (1.42)
36 weeks 2.66 (1.33) 2.59 (1.42)
4 months 2.58 (1.39) 2.51 (1.37)
Dairy, servings/day Trial entry 2.05 (1.34) 2.21 (1.52) 0.002 0.02 −0.17 (−0.30 to −0.03)
28 weeks 2.30 (1.24) 2.24 (1.39) 0.09 0.12 (−0.02 to 0.25)
36 weeks 2.42 (1.42) 2.33 (1.40) 0.24 0.09 (−0.06 to 0.24)
4 months 2.28 (1.36) 2.24 (1.42) 0.56 0.05 (−0.11 to 0.21)
Fruit, servings/dayd Trial entry 2.67 (2.07) 2.48 (1.63) 0.44 0.002 0.21 (0.08 to 0.35)
28 weeks 2.70 (1.62) 2.43 (1.74)
36 weeks 2.56 (1.47) 2.34 (1.67)
4 months 2.24 (1.64) 2.11 (1.56)
Meat and legumes,
servings/dayd
Trial entry 2.14 (1.03) 2.10 (0.94) 0.67 0.14 0.06 (−0.02 to 0.14)
28 weeks 2.17 (1.08) 2.10 (0.97)
36 weeks 2.14 (0.91) 2.08 (1.05)
4 months 2.30 (0.95) 2.29 (1.08)
Vegetables, servings/day Trial entry 4.96 (2.64) 4.82 (2.57) 0.03 0.30 0.13 (−0.12 to 0.38)
28 weeks 5.16 (2.68) 4.71 (2.37) 0.0002 0.47 (0.22 to 0.72)
36 weeks 4.87 (2.54) 4.51 (2.65) 0.003 0.40 (0.13 to 0.67)
4 months 5.63 (3.12) 5.24 (2.62) 0.003 0.50 (0.17 to 0.82)
Non-core group
foods, servings/day
Trial entry 7.51 (3.81) 7.27 (3.61) 0.01 0.10 0.29 (−0.06 to 0.65)
28 weeks 6.84 (3.24) 7.14 (3.41) 0.17 −0.24 (−0.58 to 0.10)
36 weeks 6.86 (3.54) 6.96 (3.24) 0.72 −0.06 (−0.41 to 0.28)
4 months 8.15 (3.69) 7.95 (3.76) 0.41 0.17 (−0.24 to 0.59)
Alcohol, gd Trial entry 2.25 (5.21) 2.48 (6.47) 0.59 0.20 0.07 (−0.03 to 0.17)
28 weeks 0.34 (1.35) 0.25 (0.86)
36 weeks 0.31 (1.42) 0.27 (1.06)
4 months 2.27 (4.04) 2.18 (4.92)
Dietary fibre, gd Trial entry 32.39 (12.91) 31.64 (12.43) 0.16 0.002 1.55 (0.55 to 2.56)
28 weeks 33.75 (12.39) 31.88 (12.42)
36 weeks 32.78 (11.80) 30.93 (12.89)
4 months 34.09 (13.61) 32.50 (12.68)
Carbohydrates, gd Trial entry 255.27 (90.54) 246.38 (83.50) 0.69 0.06 6.55 (−0.19 to 13.29)
28 weeks 258.11 (82.97) 255.89 (93.44)
36 weeks 253.61 (85.76) 251.43 (90.66)
4 months 247.86 (89.54) 243.25 (88.71)
Percentage energy
from carbohydratesd
Trial entry 46.85 (5.97) 46.22 (5.59) 0.23 0.39 0.19 (−0.24 to 0.62)
28 weeks 46.96 (5.33) 46.89 (5.30)
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Table 2 Food group and macronutrient consumption: between treatment group comparisona (Continued)
36 weeks 46.61 (5.44) 46.68 (5.81)
4 months 44.89 (5.91) 44.76 (6.18)
Protein, gd Trial entry 97.59 (30.65) 97.80 (30.58) 0.07 0.14 1.82 (−0.57 to 4.22)
28 weeks 100.07 (32.16) 97.56 (30.59)
36 weeks 100.13 (30.22) 97.10 (32.18)
4 months 102.67 (31.15) 101.24 (30.08)
Percentage energy
from protein
Trial entry 22.72 (3.83) 23.22 (3.88) 0.0001 0.008 −0.49 (−0.86 to −0.13)
28 weeks 22.98 (3.74) 22.82 (3.66) 0.11 0.31 (−0.07 to 0.68)
36 weeks 23.35 (3.85) 22.98 (4.04) 0.11 0.33 − 0.08 to 0.75)
4 months 23.80 (4.25) 23.87 (4.26) 0.80 −0.06 (−0.55 to 0.42)
Total Fat, gd Trial entry 65.28 (23.60) 64.33 (22.27) 0.83 0.48 0.64 (−1.14 to 2.41)
28 weeks 66.54 (22.50) 66.70 (23.62)
36 weeks 65.98 (22.14) 66.24 (23.70)
4 months 68.16 (23.68) 67.72 (23.99)
Percentage energy
from total fatd
Trial entry 27.77 (4.51) 27.97 (4.20) 0.42 0.06 −0.31 (−0.64 to 0.02)
28 weeks 28.02 (4.19) 28.45 (4.19)
36 weeks 28.13 (4.23) 28.59 (4.36)
4 months 28.76 (4.31) 29.00 (4.39)
Saturated fat, gd Trial entry 26.47 (10.98) 26.08 (10.01) 0.50 0.71 0.15 (−0.64 to 0.94)
28 weeks 26.98 (9.87) 27.37 (10.30)
36 weeks 27.10 (10.20) 27.48 (10.62)
4 months 27.49 (10.51) 27.25 (10.29)
Percentage energy
from saturated fatd
Trial entry 11.23 (2.50) 11.34 (2.38) 0.09 0.04 −0.20 (−0.38 to −0.01)
28 weeks 11.37 (2.33) 11.70 (2.41)
36 weeks 11.52 (2.41) 11.85 (2.47)
4 months 11.59 (2.43) 11.68 (2.47)
Monounsaturated fat, gd Trial entry 22.60 (8.56) 22.28 (8.13) 0.75 0.62 0.16 (−0.48 to 0.81)
28 weeks 22.99 (8.27) 23.12 (8.70)
36 weeks 22.72 (7.96) 22.81 (8.72)
4 months 23.69 (8.72) 23.65 (9.12)
Polyunsaturated fat, gd Trial entry 9.09 (3.50) 8.95 (3.59) 0.90 0.23 0.17 (−0.11 to 0.45)
28 weeks 9.31 (3.67) 9.13 (3.81)
36 weeks 9.06 (3.33) 8.89 (3.71)
4 months 9.48 (3.71) 9.43 (4.16)
aValues are mean ± SD and treatment effects are differences in means (with 95% confidence interval and P -value) by time point estimated from a linear mixed
effects model including treatment, time and treatment × time, adjusted for centre, parity and BMI.
bIncludes women who had a live birth, and who answered one or more questionnaires; excludes questionnaires with >25% missing responses, or where there was
an unrealistic energy intake reported (<4,500 or >20,000 kJ).
cWhere the treatment × time interaction was not statistically significant, it was dropped from the model.
dValues are mean ± SD and treatment effects are differences in means (with 95% confidence interval and P-value) across all time points estimated from a linear
mixed effects model including treatment and time, adjusted for centre, parity and BMI.
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attend a walking session, and 40 (14%) attended at
least one session. The median number of sessions
attended was 2 (interquartile range 1 to 7). In women
who participated in the Walking group, no serious ad-
verse effects of exercise (including syncope, chest pain,shortness of breath, vaginal bleeding or miscarriage)
were identified.
Women further randomised to the Walking group
demonstrated no significant difference in total physical
activity compared with women in the Lifestyle group
(Table 7). Commuting, housework and work-related
Table 3 Dietary micronutrient consumption: between treatment group comparisona
Outcome Time point Lifestyle advice
(n = 945)b
Standard
care (n = 928)b
Adjusted
treatment × time
interaction P-valuec
Adjusted treatment effect
P 95% CI
Caffeine, mgd Trial entry 142.59 (156.88) 136.59 (156.36) 0.57 0.57 3.68 (−8.90 to 16.26)
28 weeks 134.63 (147.21) 132.76 (147.04)
36 weeks 129.61 (141.89) 128.55 (140.66)
4 months 202.78 (191.12) 191.83 (185.43)
Sodium, mgd Trial entry 2713.21 (1080.73) 2644.16 (1102.75) 0.86 0.10 70.55 (−13.71 to 154.81)
28 weeks 2684.04 (1038.11) 2651.08 (1048.43)
36 weeks 2704.91 (1059.82) 2620.33 (1045.35)
4 months 2822.92 (1164.27) 2759.30 (1092.84)
Calcium, mg Trial entry 930.81 (388.80) 963.43 (429.48) 0.007 0.11 −32.10 (−71.25 to 7.04)
28 weeks 1009.34 (366.54) 984.56 (400.48) 0.04 40.73 (1.57 to 79.88)
36 weeks 1031.14 (421.66) 1003.76 (404.85) 0.15 31.99 (−11.04 to 75.02)
4 months 1007.13 (415.11) 990.64 (416.75) 0.37 21.26 (−25.14 to 67.67)
Iron, mgd Trial entry 13.79 (4.79) 13.57 (4.61) 0.83 0.08 0.33 (−0.04 to 0.70)
28 weeks 14.21 (4.56) 13.94 (4.92)
36 weeks 14.03 (4.48) 13.69 (5.04)
4 months 14.51 (4.79) 14.08 (4.77)
Zinc, mgd Trial entry 11.71 (3.69) 11.71 (3.56) 0.08 0.11 0.23 (−0.06 to 0.52)
28 weeks 12.14 (3.70) 11.82 (3.70)
36 weeks 12.12 (3.68) 11.75 (3.90)
4 months 12.36 (3.74) 12.12 (3.62)
Magnesium, mgd Trial entry 344.03 (116.89) 342.67 (116.44) 0.11 0.06 9.07 (−0.20 to 18.33)
28 weeks 356.11 (110.62) 344.98 (119.15)
36 weeks 353.11 (112.18) 340.31 (117.27)
4 months 364.02 (119.85) 354.13 (118.78)
Phosphorus, mgd Trial entry 1586.85 (497.80) 1595.95 (515.48) 0.08 0.16 28.14 (−11.27 to 67.56)
28 weeks 1657.50 (493.47) 1618.65 (509.91)
36 weeks 1671.51 (516.33) 1626.25 (518.62)
4 months 1689.35 (528.98) 1655.95 (514.58)
Potassium, mg Trial entry 3591.78 (1220.73) 3570.31 (1169.87) 0.05 0.69 23.15 (−90.33 to 136.63)
28 weeks 3723.05 (1129.40) 3586.57 (1223.47) 0.004 173.10 (54.97 to 291.23)
36 weeks 3674.33 (1131.83) 3541.08 (1185.20) 0.01 158.03 (38.14 to 277.92)
4 months 3781.35 (1271.44) 3657.89 (1165.91) 0.06 127.88 (−4.96 to 260.72)
Iodine, μgd Trial entry 204.05 (108.94) 205.81 (105.00) 0.37 0.38 3.54 (−4.36 to 11.44)
28 weeks 210.93 (97.92) 206.26 (96.36)
36 weeks 215.94 (101.27) 209.86 (99.91)
4 months 214.81 (109.29) 212.34 (102.24)
Vitamin A Active
Equivalent, μgd
Trial entry 1475.35 (974.00) 1404.15 (752.52) 0.16 0.003 110.40 (36.48 to 184.32)
28 weeks 1605.54 (1323.79) 1424.89 (890.08)
36 weeks 1462.83 (821.57) 1363.63 (877.70)
4 months 1658.00 (1077.44) 1539.68 (852.02)
Retinol, μgd Trial entry 366.23 (558.09) 336.37 (311.97) 0.34 0.33 18.56 (−18.64 to 55.75)
28 weeks 422.55 (1087.70) 372.54 (607.22)
Dodd et al. BMC Medicine 2014, 12:161 Page 10 of 19
http://www.biomedcentral.com/1741-7015/12/161
Table 3 Dietary micronutrient consumption: between treatment group comparisona (Continued)
36 weeks 349.30 (400.65) 369.78 (508.35)
4 months 376.11 (626.42) 371.01 (464.27)
Vitamin B1 (thiamine), mg
d Trial entry 1.55 (0.57) 1.52 (0.56) 0.50 0.07 0.04 (−0.00 to 0.08)
28 weeks 1.61 (0.55) 1.57 (0.61)
36 weeks 1.62 (0.55) 1.56 (0.62)
4 months 1.58 (0.57) 1.54 (0.56)
Vitamin B2 (riboflavin), mg Trial entry 2.14 (0.84) 2.19 (0.87) 0.02 0.22 −0.05 (−0.13 to 0.03)
28 weeks 2.33 (0.79) 2.28 (0.89) 0.05 0.08 (−0.00 to 0.17)
36 weeks 2.37 (0.86) 2.33 (0.87) 0.23 0.06 (−0.03 to 0.15)
4 months 2.34 (0.87) 2.29 (0.85) 0.24 0.06 (−0.04 to 0.15)
Niacin, mgd Trial entry 22.60 (7.43) 22.49 (7.24) 0.32 0.09 0.49 (−0.08 to 1.07)
28 weeks 23.02 (7.61) 22.57 (7.47)
36 weeks 23.04 (7.05) 22.35 (7.75)
4 months 23.89 (7.47) 23.25 (7.08)
Vitamin C, mgd Trial entry 165.11 (117.86) 152.24 (90.04) 0.50 0.02 8.87 (1.40 to 16.34)
28 weeks 158.26 (91.27) 147.34 (100.64)
36 weeks 149.35 (87.94) 142.60 (99.13)
4 months 139.11 (89.17) 133.80 (77.94)
Vitamin E, mgd Trial entry 7.37 (2.90) 7.35 (2.91) 0.71 0.17 0.16 (−0.07 to 0.38)
28 weeks 7.58 (2.77) 7.39 (2.97)
36 weeks 7.40 (2.71) 7.23 (2.85)
4 months 7.94 (3.10) 7.74 (3.14)
Folate, μgd Trial entry 529.62 (206.87) 520.74 (210.02) 0.49 0.03 17.49 (1.26 to 33.71)
28 weeks 545.59 (203.52) 528.35 (212.15)
36 weeks 540.67 (196.49) 522.05 (213.62)
4 months 544.99 (206.99) 528.74 (201.97)
Folate food, μgd Trial entry 401.20 (161.35) 395.15 (160.90) 0.24 0.02 15.13 (2.14 to 28.12)
28 weeks 410.82 (161.38) 394.97 (161.04)
36 weeks 402.80 (150.79) 388.02 (161.70)
4 months 420.96 (164.11) 406.71 (156.54)
aValues are mean ± SD and treatment effects are differences in means (with 95% confidence interval and P-value) by time point estimated from a linear mixed
effects model including treatment, time and treatment × time, adjusted for centre, parity and body mass index.
bIncludes women who had a live birth, and who answered one or more questionnaires; excludes questionnaires with >25% missing responses, or where there was
an unrealistic energy intake reported (<4,500 or >20,000 kJ).
cWhere the treatment × time interaction was not statistically significant, it was dropped from the model.
dValues are mean ± SD and treatment effects are differences in means (with 95% confidence interval and P-value) across all time points estimated from a linear
mixed effects model including treatment and time, adjusted for centre, parity and BMI.
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evidence to suggest that treatment effects varied over
time for leisure activities (interaction P = 0.04), but no
significant differences were identified between treatment
groups at any time point in post hoc testing.
Discussion
Our randomised trial is the largest reported to date
evaluating specific dietary and physical activity effects of
an antenatal lifestyle intervention for women who are
overweight or obese during pregnancy, utilising robustmethodology, and is the first to compare differing inten-
sities of provision of support for increasing physical
activity. The findings indicate that provision of an inter-
vention during pregnancy is effective in improving ma-
ternal diet. Specifically, our data suggest that intake of
fibre, saturated fat, fruits and vegetables, micronutrient
intake, and overall maternal diet quality, as measured by
the HEI, improved following the intervention, in the ab-
sence of significant changes in energy intake. Although
some changes in diet quality and micronutrient consump-
tion were evident during pregnancy, the improvements
Table 4 Healthy eating index: between treatment group comparisona
Outcome Time point Lifestyle advice
(n = 945)b
Standard
care (n = 928)b
Adjusted
treatment × time
interaction P-valuec
Adjusted treatment effect
P 95% CI
HEI, range 0 to 100 Trial entry 72.11 (7.71) 72.80 (7.07) <0.0001 0.06 −0.67 (−1.37 to 0.03)
28 weeks 73.35 (6.62) 71.86 (7.01) <0.0001 1.58 (0.89 to 2.27)
36 weeks 72.95 (6.82) 71.17 (7.69) <0.0001 1.77 (1.01 to 2.53)
4 months 72.83 (7.56) 72.15 (7.47) 0.41 0.35 (−0.48 to 1.18)
Total fruit, range 0 to 5 Trial entry 4.50 (1.02) 4.48 (1.03) 0.003 0.567 0.03 (−0.07 to 0.13)
28 weeks 4.63 (0.89) 4.42 (1.11) 0.0001 0.20 (0.10 to 0.30)
36 weeks 4.58 (0.97) 4.34 (1.18) <0.0001 0.24 (0.13 to 0.35)
4 months 4.27 (1.23) 4.11 (1.33) 0.07 0.14 (−0.01 to 0.28)
Whole fruit, range 0 to 5 Trial entry 4.56 (1.09) 4.57 (1.05) 0.0002 0.77 −0.01 (−0.12 to 0.09)
28 weeks 4.68 (0.94) 4.50 (1.15) 0.0003 0.19 (0.09 to 0.30)
36 weeks 4.64 (1.03) 4.42 (1.24) <0.0001 0.24 (0.12 to 0.35)
4 months 4.43 (1.18) 4.35 (1.24) 0.30 0.07 (−0.06 to 0.21)
Total vegetables, range 0 to 5d Trial entry 4.86 (0.58) 4.88 (0.50) 0.06 0.12 0.03 (−0.01 to 0.06)
28 weeks 4.91 (0.44) 4.88 (0.48)
36 weeks 4.88 (0.49) 4.81 (0.62)
4 months 4.94 (0.31) 4.89 (0.45)
Dark-green and orange
Vegetables and legumes,
range 0 to 5d
Trial entry 4.76 (0.76) 4.72 (0.84) 0.12 0.0006 0.10 (0.04 to 0.16)
28 weeks 4.82 (0.64) 4.73 (0.78)
36 weeks 4.76 (0.77) 4.64 (0.93)
4 months 4.89 (0.46) 4.78 (0.75)
Total grains, range 0 to 5d Trial entry 3.88 (0.93) 3.89 (0.91) 0.24 0.55 −0.02 (−0.09 to 0.05)
28 weeks 3.88 (0.91) 3.95 (0.88)
36 weeks 3.93 (0.91) 3.92 (0.93)
4 months 3.80 (1.00) 3.78 (1.04)
Whole grains, range 0 to 5d Trial entry 0.71 (0.88) 0.71 (0.83) 0.23 0.14 0.05 (−0.02 to 0.11)
28 weeks 0.74 (0.86) 0.67 (0.83)
36 weeks 0.82 (0.90) 0.71 (0.91)
4 months 0.81 (0.87) 0.78 (0.88)
Milk, range 0 to 10 Trial entry 6.54 (2.80) 6.98 (2.82) <0.0001 0.002 −0.42 (−0.69 to −0.16)
28 weeks 7.37 (2.61) 7.15 (2.70) 0.04 0.29 (0.01 to 0.56)
36 weeks 7.48 (2.49) 7.34 (2.69) 0.45 0.10 (−0.17 to 0.38)
4 months 7.23 (2.70) 7.01 (2.69) 0.28 0.17 (−0.14 to 0.48)
Meat and beans, range 0 to 10d Trial entry 9.59 (1.20) 9.61 (1.07) 0.24 0.67 0.02 (−0.06 to 0.10)
28 weeks 9.59 (1.16) 9.55 (1.16)
36 weeks 9.60 (1.13) 9.46 (1.26)
4 months 9.74 (0.96) 9.74 (0.99)
Oils, range 0 to 10d Trial entry 5.48 (3.19) 5.45 (3.25) 0.24 0.15 0.18 (−0.07 to 0.42)
28 weeks 5.50 (3.17) 5.27 (3.18)
36 weeks 5.42 (3.27) 4.99 (3.25)
4 months 5.69 (3.18) 5.46 (3.26)
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Saturated fat, range 0 to 10d Trial entry 5.48 (3.00) 5.36 (2.96) 0.08 0.07 0.21 (−0.02 to 0.44)
28 weeks 5.31 (2.88) 4.91 (2.90)
36 weeks 5.04 (3.04) 4.70 (3.02)
4 months 5.01 (3.02) 4.97 (3.00)
Sodium, range 0 to 10d Trial entry 6.10 (2.43) 6.22 (2.43) 0.77 0.34 −0.09 (−0.27 to 0.10)
28 weeks 6.28 (2.42) 6.27 (2.32)
36 weeks 6.10 (2.44) 6.28 (2.38)
4 months 5.80 (2.63) 5.91 (2.46)
Calories from solid fats,
alcohol and added sugar
(SoFAAS), range 0 to 20d
Trial entry 15.64 (3.79) 15.94 (3.60) 0.150 0.56 −0.08 (−0.33 to 0.18)
28 weeks 15.63 (3.24) 15.55 (3.45)
36 weeks 15.69 (3.20) 15.57 (3.51)
4 months 16.21 (3.33) 16.37 (3.22)
aValues are mean ± SD and treatment effects are differences in means (with 95% confidence interval and P-value) by time point estimated from a linear mixed
effects model including treatment, time and treatment × time, adjusted for centre, parity and BMI.
bIncludes women who had a live birth, and who answered one or more questionnaires; excludes questionnaires with >25% missing responses, or where there was
an unrealistic energy intake reported (<4,500 or >20,000 kJ).
cWhere the treatment × time interaction was not statistically significant, it was dropped from the model.
dValues are mean ± SD and treatment effects are differences in means (with 95% confidence interval and P-value) across all time points estimated from a linear
mixed effects model including treatment and time, adjusted for centre, parity and BMI.
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and there were no differences identified in maternal diet-
ary glycaemic load or index. There was little evidence to
suggest that the effect of the intervention differed be-
tween overweight and obese women.
The findings of the LIMIT Trial also indicate that
provision of a lifestyle intervention during pregnancy
was effective in increasing total physical activity, largely
through increasing household activity, approximately
equivalent to an additional 15 to 20 minutes brisk walking
on most days of the week, an effect that was more pro-
nounced among obese women. Although women were
provided with access to a structured walking group in
the nested component of the trial, attendance was poor,
with women preferring a less supervised approach to
physical activity.
We have previously reported an 18% relative risk re-
duction in infant birth weight above 4 kg following the
provision of an antenatal intervention for pregnant
women who are overweight or obese [41]. This observed
effect on infant birth weight appears to have been me-
diated by changes in maternal diet quality and physical
activity, despite the fact that maternal gestational weight
gain [41], total energy intake during pregnancy, and
dietary GL, did not differ significantly between the two
randomised groups.
Detailed dietary changes following antenatal interven-
tions to women who are overweight or obese have been
poorly reported to date. To our knowledge, the current
randomised trial is one of the few studies presenting
detailed macronutrient, micronutrient, food group, dietaryquality, and glycaemic index or glycaemic load informa-
tion in an overweight or obese pregnant population. There
is evidence from non-pregnant populations that subtle
differences in HEI may be associated with improve-
ments in health and reduced complications associated
with type 2 diabetes [58]. However, other studies report
larger differences in diet quality, in association with
changes in blood pressure and other measures of car-
diometabolic disease, including cholesterol [59,60]. We
previously identified a decline in maternal HEI over
the duration of pregnancy, which was maintained into
the postpartum period, and was positively correlated with
socioeconomic status [14]. While the currently reported
HEI scores are higher than those previously derived
from a far smaller subgroup of participants [14], the
trend towards a decline in diet quality across preg-
nancy and into the postpartum period was also evident
for all the women receiving standard care.
Overall, the existing literature supports the positive effect
of lifestyle interventions during pregnancy for women who
are overweight or obese in improving a range of measures
of dietary intake [40,61-63], even in the absence of changes
in gestational weight gain and overall energy intake [61,62].
Specific dietary modifications reported include reduced
consumption of saturated fats [40,61-63] and increased
consumption of protein [40,61,63]. The currently reported
findings are consistent with maternal total energy intake
observed in other studies [61,63], and although the percent-
age energy derived from fat was similar to that reported by
Wolff and colleagues [63], it was lower than that reported
by both Guelinckx [61] and Poston [40]. These differences
Table 5 Glycaemic load and glycaemic index: between treatment group comparisona
Outcome Time point Lifestyle advice
(n = 945)b
Standard
care (n = 928)b
Adjusted treatment × time
interaction P-valuec
Adjusted treatment effect
P 95% CI
Glycaemic load Trial entry 129.46 (47.84) 124.92 (45.07) 0.45 0.15 2.62 (−0.94 to 6.18)
28 weeks 130.10 (44.55) 129.86 (50.67)
36 weeks 126.96 (44.90) 127.12 (48.60)
4 months 123.56 (47.92) 121.86 (47.71)
Glycaemic index Trial entry 50.57 (3.65) 50.51 (3.59) 0.17 0.10 −0.22 (−0.48 to 0.04)
28 weeks 50.19 (3.36) 50.48 (3.45)
36 weeks 49.90 (3.47) 50.32 (3.65)
4 months 49.55 (3.92) 49.71 (4.17)
aValues are mean ± SD and treatment effects are differences in means (with 95% confidence interval and P-value) across all time points estimated from a linear
mixed effects model including treatment and time, adjusted for centre, parity and BMI.
bIncludes women who had a live birth, and who answered one or more questionnaires; excludes questionnaires with >25% missing responses, or where there was
an unrealistic energy intake reported (<4,500 or >20,000 kJ).
cWhere the treatment × time interaction was not statistically significant, it was dropped from the model.
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LIMIT cohort of women being predominantly of white eth-
nicity, and having lower mean BMI at trial entry.
The developmental over-nutrition hypothesis (also
termed the Pedersen Hypothesis) was first proposed inTable 6 Self-reported physical activity: between treatment gr
Outcome Time point Lifestyle advice
(n = 974)b
Standard car
(n = 950)b
Commuting activityd Trial entry 286.15 (386.14) 245.40 (277.01
28 weeks 234.95 (234.09) 219.74 (226.69
36 weeks 212.05 (257.66) 228.88 (314.25
4 months 309.87 (331.10) 330.50 (422.89
Leisure activity Trial entry 1081.25 (1423.50) 1022.28 (1282
28 weeks 1016.04 (1310.73) 862.28 (1092.8
36 weeks 788.66 (961.96) 777.53 (900.00
4 months 1281.07 (1303.30) 1163.67 (1249
Household activity Trial entry 3290.48 (3139.01) 3148.30 (3093
28 weeks 3229.92 (3066.10) 2988.91 (2961
36 weeks 3158.49 (2954.16) 2813.98 (2934
4 months 4756.43 (3831.12) 4677.16 (3881
Work activityd Trial entry 4697.83 (3093.41) 4405.76 (2818
28 weeks 4326.30 (2707.53) 4279.65 (2660
36 weeks 4032.73 (2484.61) 4059.23 (2593
4 months 3041.02 (2505.86) 3204.85 (2706
Total activity Trial entry 7587.63 (4573.52) 7259.93 (4145
28 Weeks 7010.32 (3950.39) 6742.48 (3836
36 Weeks 5819.82 (3954.63) 5518.10 (3844
4 Months 6530.19 (4336.80) 6317.00 (4498
aValues are mean ± SD and treatment effects are differences in means (with 95% co
mixed effects model including treatment and time, adjusted for centre, parity and B
bIncludes women who had a live birth, and who answered one or more questionna
reported exceeded the number of hours in a week.
cWhere the treatment × time interaction was not statistically significant, it was drop
dWhere women participated in these activities.1954 [64] in an attempt to explain the relationship
between maternal diabetes during pregnancy and fetal
overgrowth, principally increased adiposity. Under this
hypothesis, maternal hyperglycaemia is associated with
increased placental transfer of glucose, resulting inoup comparisona
e Adjusted treatment × time
interaction P-valuec
Adjusted treatment effect
P 95% CI
) 0.56 0.55 11.83 (−26.75 to 50.42)
)
)
)
.32) 0.22 0.06 79.33 (−2.09 to 160.75)
6)
)
.04)
.46) 0.59 0.01 265.60 (61.36 to 469.84)
.08)
.20)
.09)
.43) 0.40 0.52 80.85 (−163.12 to 324.83)
.85)
.77)
.89)
.34) 0.99 0.01 359.76 (74.87 to 644.65)
.85)
.79)
.15)
nfidence interval and P-value) across all time points estimated from a linear
MI.
ires; excludes questionnaires where the total hours of activity per week
ped from the model.
Figure 2 Flow of participants through the nested randomised trial.
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http://www.biomedcentral.com/1741-7015/12/161fetal hyperglycaemia and increased insulin production,
with the resultant effect being an increase in insulin-
mediated fetal growth. More recently, the hypothesis
has been expanded to recognise the potential meta-
bolic impact of maternal obesity [65], which shares a
similar metabolic milieu, characterised by insulin resist-
ance, hyperglycaemia, hyperlipidaemia and a low-grade
state of chronic inflammation, which in turn has been
documented to influence the availability and transfer
of nutrients to the developing fetus [65].
The findings of the LIMIT Trial did not identify differ-
ences in maternal dietary glycaemic index or glycaemic load
following antenatal lifestyle intervention, which is in
contrast to other reports in the literature [22,40]. The
effects of maternal dietary glycaemic index on pregnancy
outcomes generally, and measures of fetal and neonatal
growth more specifically, are uncertain. Although some
studies have identified an association between maternal
consumption of a low glycaemic index diet and reduced
gestational weight gain [22,23], lower infant birth weight
[24] and reduced neonatal adiposity as measured by thigh
circumference [66], these findings are not universal, with
others reporting no evidence of effect on infant birth
weight [23,25-27,40].
The contribution to fetal growth of other fuel substrates,
including free fatty acids, triglycerides and amino acids, has
also been recognised [64]. Fatty acids may be of importance
as a fuel substrate for obese pregnant women, who have
demonstrated increased reliance on lipid metabolism [67]
in order to meet the energy requirements of pregnancy,
which are only minimally accounted for by changes in diet-
ary energy intake [68]. This is of particular relevance, giventhe currently reported findings of increased consumption
of dietary fibre and reduced saturated fat intake, both of
which could plausibly improve maternal insulin resistance
[69] and contribute to our previously reported reduction in
high infant birth weight following antenatal dietary and
physical activity advice [41]. Furthermore, relatively modest
changes in nutrient consumption and diet quality may dir-
ectly affect clinical outcomes during pregnancy, particularly
fetal and early infant growth. Reports in the literature indi-
cate that maternal consumption of a diet high in polyunsat-
urated fatty acids is associated with a reduction in early
childhood adiposity as measured by skinfold thickness [70],
and is predictive of fat mass determined by dual energy
X-ray absorptiometry at the ages of 4 and 6 years [71].
Together with our findings, these reports highlight the
potential impact of relatively modest changes in mater-
nal diet quality on in utero growth, birth weight and
future childhood adiposity.
There is a lack of consensus as to the most appropriate
tool to assess physical activity, both in the general popula-
tion, and more specifically during pregnancy [72]. Although
physical activity questionnaires are a cost-effective method
of assessment, particularly for use in large-scale studies,
concerns have been raised about them over-estimating
activity [73]. The use of pedometers and accelerometers
has been advocated as a more objective tool, although
these are not without their limitations, including poor
measurement of upper body movement and stationary
exercise [72]. Furthermore, the two methods do not appear
interchangeable, particularly for overweight and obese
pregnant women, with poorly reported correlation in
step counts for any individual [74].
Table 7 Self-reported physical activity of participants in nested randomised trial: between treatment group comparisona
Outcome Time
point
Walking group
(n = 257)b
Information
only (n = 269)b
Adjusted treatment × time
interaction P-valuec
Adjusted treatment effect
P 95% CI
Commuting activityd Trial entry 227.30 (281.27) 240.47 (243.97) 0.24 0.63 17.41 (−54.57 to 89.39)
28 weeks 218.05 (176.55) 200.32 (287.47)
36 weeks 292.52 (366.32) 185.01 (178.98)
4 months 248.44 (263.20) 390.00 (512.82)
Leisure activitye Trial entry 1048.02 (1311.53) 877.42 (1146.34) 0.04 0.11 174.72 (−41.93 to 391.38)
28 weeks 1048.30 (1248.43) 911.11 (1212.73) 0.36 108.50 (−125.45 to 342.44)
36 weeks 796.16 (1011.25) 727.39 (810.12) 0.67 52.10 (−188.17 to 292.38)
4 months 1178.16 (1071.98) 1374.64 (1411.67) 0.08 −236.04 (−503.44 to 31.37)
Household activity Trial entry 3437.45 (3353.79) 2961.20 (2924.20) 0.19 0.16 294.44 (−114.88 to 703.76)
28 weeks 3441.23 (3085.54) 2697.92 (2732.72)
36 weeks 3208.16 (3005.22) 2951.82 (3111.69)
4 months 4862.53 (4204.93) 4672.32 (3766.02)
Work-related activityd Trial entry 4440.89 (2743.25) 4888.99 (3130.39) 0.19 0.26 −259.57 (−710.22 to 191.08)
28 weeks 4121.12 (2359.13) 4409.20 (2735.41)
36 weeks 3512.04 (1852.27) 4035.94 (2274.21)
4 months 3454.71 (2619.25) 3144.64 (2212.72)
Total activity Trial entry 7524.07 (4657.16) 7311.45 (4318.89) 0.75 0.40 247.31 (−332.35 to 826.98)
28 weeks 7169.05 (3823.28) 6564.51 (3898.19)
36 weeks 5888.77 (3688.15) 5479.91 (4066.69)
4 months 6526.84 (4637.30) 6641.77 (4494.63)
aValues are mean ± SD and treatment effects are differences in means (with 95% confidence interval and P-value) across all time points estimated from a linear
mixed effects model including treatment and time, adjusted for centre, parity and BMI.
bIncludes women who had a live birth, and who answered one or more questionnaires; excludes questionnaires where the total hours of activity per week
reported exceeded the number of hours in a week.
cWhere the treatment × time interaction was not statistically significant, it was dropped from the model.
dWhere women participated in these activities.
eValues are mean ± SD and treatment effects are differences in means (with 95% confidence interval and P-value) by time point estimated from a linear mixed
effects model including treatment, time and treatment × time, adjusted for centre, parity and BMI.
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duction in physical activity as pregnancy advances
[39], particularly among women who are overweight
or obese [40] compared with lean women [38,39]. Re-
ports suggest that domestic and childcare activities
constitute up to 50% of total energy expenditure and
activity during pregnancy [75,76], increasing to 65% in
women who are obese [77]. It is therefore important
that questionnaires include this activity category [75],
particularly as other assessment measures, including both
pedometers and accelerometers, are poor at identifying
low-intensity activity [72].
A potential limitation of our trial is the reliance on
self-reported questionnaire assessment of both dietary
intake and physical activity. However, the purpose was
to compare the effects of an antenatal intervention
with standard care, and more detailed assessments of
either dietary intake or physical activity were not con-
sidered feasible, given the sample size involved and the
multiple time points assessed. A general concern withdietary and physical activity studies, particularly those
relying on self-completed questionnaires, relates to the
potential for recall bias, which may be differentially
evident according to treatment group allocation. Even
though women were asked about their dietary intake in the
past 12 months at the time of trial entry, it is possible that
the baseline assessment of both dietary intake and physical
activity were influenced by knowledge of treatment group
allocation. Although there was a fall-off in questionnaire
response rates over pregnancy and the postpartum
period, the proportion of women contributing data to
the analyses was high. Furthermore, the women included
in the analysis had similar baseline characteristics to,
and can therefore be considered representative of, the
complete randomised groups [41].
It is possible that women in the intervention group
modified their self-reported dietary intake and physical
activity following notification of the treatment group
in order to provide ‘desirable’ answers and those that
would be subsequently consistent with the content of
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we would have anticipated changes also to be reported
in the consumption of refined carbohydrates and sugar-
sweetened beverages, which was not observed. We ob-
served an increase in reported physical activity among
women in the intervention group, which was consistent
across all time points, including trial entry. This may
reflect variation in the timing of completion of the trial
entry questionnaire, with women randomised to the
Lifestyle Advice group potentially increasing their activity
in the period between randomisation and questionnaire
return (up to 10 days), prior to attendance for their first
intervention session. It may also reflect a chance occur-
rence, particularly because, although dietary question-
naires were completed within the same time period, no
baseline differences in dietary intake measures were
observed between the two treatment groups. True dif-
ferences in physical activity of this magnitude between
treatment groups at trial entry are unlikely, given our
large sample size and the degree of balance achieved
for other baseline characteristics.Conclusions
To date, there has been a lack of detailed information
from randomised trials outlining specific effects on ma-
ternal diet and physical activity, following an antenatal
intervention for women who are overweight or obese.
While our results indicate that provision of an antenatal
dietary and lifestyle intervention is effective in improving
maternal diet quality, food group, macronutrient and
micronutrient intake, and physical activity during preg-
nancy, many of these improvements were not maintained
at 4 months postpartum, highlighting the need for add-
itional interventions during this important period of
adjustment for women and their families.
We consider the observed changes in diet quality and
physical activity during pregnancy, although modest, to
be of clinical significance, given our reported findings of
a reduced risk of infant birth weight above 4 kg for preg-
nant women who are overweight or obese [41], and such
changes are likely to be far more achievable from a public
health perspective than more restrictive approaches to lim-
iting gestational weight gain. It will therefore be important
to continue to follow up the infants born to women who
participated in this trial to evaluate the longer-term health
effects of the changes observed in maternal diet and phys-
ical activity achieved during pregnancy, particularly in rela-
tion to subsequent childhood obesity.Additional files
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